Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.18)
# 465
Out of 4,974 analysts
79
Total ratings
52.73%
Success rate
15.39%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $52.79 | +51.54% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.31 | +125.99% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $10.29 | +74.93% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $25.79 | +31.83% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $39.34 | +39.81% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $24.98 | +28.10% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $145.09 | +27.51% | 2 | Apr 24, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $53.33 | -6.24% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $15.55 | +221.54% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $112.98 | +10.64% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $57.62 | +82.23% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $570.48 | +105.97% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $72.47 | +17.29% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $31.99 | +175.09% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $142.46 | +93.74% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.98 | +1,076.47% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $281.95 | -17.72% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $85.89 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $114.61 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.82 | -29.58% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.13 | +348.34% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $10.07 | +2,382.62% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.09 | +817.43% | 1 | Feb 14, 2018 |
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $52.79
Upside: +51.54%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.31
Upside: +125.99%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $10.29
Upside: +74.93%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $25.79
Upside: +31.83%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $39.34
Upside: +39.81%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $24.98
Upside: +28.10%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $145.09
Upside: +27.51%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $53.33
Upside: -6.24%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $15.55
Upside: +221.54%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $112.98
Upside: +10.64%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $57.62
Upside: +82.23%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $570.48
Upside: +105.97%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $72.47
Upside: +17.29%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $31.99
Upside: +175.09%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $142.46
Upside: +93.74%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.98
Upside: +1,076.47%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $281.95
Upside: -17.72%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $85.89
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $114.61
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.82
Upside: -29.58%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.13
Upside: +348.34%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $10.07
Upside: +2,382.62%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.09
Upside: +817.43%